IL6 and cancer: Although some of the structural modifications such as introducing different substituents to the alpha-position of the gamma-lactone ring enhance the anti-cancer effects of the brevilin A synthetic compounds [20], whether these synthetic or semi-synthetic compounds would also target the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay has not been studied.